Ascus uses its proprietary technology platform to resolve the complexities in the native microbial communities living in highly productive and healthy animals. From these curated insights, efficacious native microorganisms are selected and isolated from animal samples and developed into products. These novel, multi-strain and naturally occurring whole microbe products are shelf stabilized and compatible with standard in-feed delivery systems. This method is the first of its kind in the animal health and nutrition industry, where most microbial products on the market are not developed based on a comprehensive understanding of animal microbiomes.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/28/20 | $46,000,000 |
Anterra Capital Cavallo Ventures Formation 8 Temasek  | undisclosed |
